These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31582260)

  • 1. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement.
    Hegele RA; Borén J; Ginsberg HN; Arca M; Averna M; Binder CJ; Calabresi L; Chapman MJ; Cuchel M; von Eckardstein A; Frikke-Schmidt R; Gaudet D; Hovingh GK; Kronenberg F; Lütjohann D; Parhofer KG; Raal FJ; Ray KK; Remaley AT; Stock JK; Stroes ES; Tokgözoğlu L; Catapano AL
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):50-67. PubMed ID: 31582260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Perrone Filardi P; Riccardi G; Storey RF; Wood D;
    Atherosclerosis; 2011 Jul; 217 Suppl 1():S1-44. PubMed ID: 21723445
    [No Abstract]   [Full Text] [Related]  

  • 3. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman M; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D; ;
    Atherosclerosis; 2011 Jul; 217(1):3-46. PubMed ID: 21882396
    [No Abstract]   [Full Text] [Related]  

  • 4. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).
    ; Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL
    Atherosclerosis; 2016 Oct; 253():281-344. PubMed ID: 27594540
    [No Abstract]   [Full Text] [Related]  

  • 5. Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.
    Pedro-Botet J; Ascaso JF; Blasco M; Brea Á; Díaz Á; Hernández-Mijares A; Pintó X; Millán J;
    Clin Investig Arterioscler; 2020; 32(5):209-218. PubMed ID: 32037300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ECS guidelines 2016 - dyslipidaemias].
    Sinning D; Landmesser U
    Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis.
    Pirillo A; Svecla M; Catapano AL; Holleboom AG; Norata GD
    Cardiovasc Res; 2021 Mar; 117(4):1033-1045. PubMed ID: 32886765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA).
    Klug E; Raal FJ; Marais AD; Smuts CM; Schamroth C; Jankelow D; Blom DJ; Webb DA
    S Afr Med J; 2018 Oct; 108(11b):973-1000. PubMed ID: 30421699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SCARB1 Gene Variants Are Associated With the Phenotype of Combined High High-Density Lipoprotein Cholesterol and High Lipoprotein (a).
    Yang X; Sethi A; Yanek LR; Knapper C; Nordestgaard BG; Tybjærg-Hansen A; Becker DM; Mathias RA; Remaley AT; Becker LC
    Circ Cardiovasc Genet; 2016 Oct; 9(5):408-418. PubMed ID: 27651445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of dyslipidaemias -  present and future. Guidelines of the Angiology Section of the Slovak Medical Chamber (2013)].
    Gavornik P; Dukát A; Gašpar L;
    Vnitr Lek; 2013 Oct; 59(10):932-8. PubMed ID: 24164369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new joint EAS/ESC guidelines for the management of dyslipidaemias.
    Catapano AL; Chapman J; Wiklund O; Taskinen MR
    Atherosclerosis; 2011 Jul; 217(1):1. PubMed ID: 21722901
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine.
    Peterlin A; Petrovič D; Peterlin B
    Curr Vasc Pharmacol; 2019; 17(1):25-28. PubMed ID: 29412113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
    Chan DC; Barrett PH; Watts GF
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations of the European Society of Cardiology and the European Atherosclerosis Society on Cardiovascular Disease Prevention and Management of Dyslipidemias. for the Diagnosis of Atherosclerosis and Dyslipidemia Treatment (2016): Basic S.G.].
    Bubnova MG; Kukharchuk VV
    Kardiologiia; 2017 Mar; 57(3):85-89. PubMed ID: 28762942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
    Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WMM; Vlachopoulos C; Wood DA; Zamorano JL; Cooney MT;
    Eur Heart J; 2016 Oct; 37(39):2999-3058. PubMed ID: 27567407
    [No Abstract]   [Full Text] [Related]  

  • 16. [Atherogenic dyslipidemia: a multidisciplinary consensus panel].
    Foro Dislipidemia Aterogénica
    Clin Investig Arterioscler; 2013; 25(2):83-91. PubMed ID: 23747118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and Treatment of Dyslipidaemias in Athletes.
    Christou GA; Kouidi EJ; Deligiannis AP; Kiortsis DN
    Curr Vasc Pharmacol; 2017; 15(3):238-247. PubMed ID: 28137212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].
    Ural D
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):293-7. PubMed ID: 22951844
    [No Abstract]   [Full Text] [Related]  

  • 19. [The role of atherogenic dyslipidaemia in clinical practice guidelines].
    Pedro-Botet J; Mantilla-Morató T; Díaz-Rodríguez Á; Brea-Hernando Á; González-Santos P; Hernández-Mijares A; Pintó X; Millán Núñez-Cortés J
    Clin Investig Arterioscler; 2016; 28(2):65-70. PubMed ID: 26949069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement.
    Bruckert E
    Atheroscler Suppl; 2014 Sep; 15(2):26-32. PubMed ID: 25257074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.